MiR-452-5p Promotes Colorectal Cancer Progression by Regulating an ERK/MAPK Positive Feedback Loop

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Mar 4

PMID 33658394

Citations 16

Authors

Xin Lin

Lu Han

Chuncai Gu

Yihong Lai

Qiuhua Lai

Qingyuan Li

Chengcheng He

Yan Meng

Lei Pan

Side Liu

Aimin Li

Affiliations

Soon will be listed here.

Abstract

Background: MiR-452-5p plays an essential role in the development of a variety of tumors, but little is known about its biological function and mechanism in colorectal cancer (CRC).

Methods: The expression levels of miR-452-5p in CRC tissues and cells were detected by real-time quantitative PCR (qRT-PCR). Besides, the biological effects of miR-452-5p on CRC were investigated by functional experiments and . Furthermore, bioinformatics analysis, dual-luciferase reporter assay, chromatin immunecipitation assay, western blotting and recovery experiments were implemented to investigate the underlying molecular mechanism.

Results: The expression level of miR-452-5p was up-regulated in CRC tissues. MiR-452-5p promoted CRC cell proliferation, cell cycle transition and chemoresistance, and inhibited cell apoptosis. Moreover, miR-452-5p directly targeted PKN2 and DUSP6 and subsequently activated the ERK/MAPK signaling pathway, and it was transcriptionally regulated by c-Jun.

Conclusion: To conclude, miR-452-5p expression is up-regulated in CRC, which promotes the progression of CRC by activating the miR-452-5p-PKN2/DUSP6-c-Jun positive feedback loop. These findings indicate that miR-452-5p may act as a potential therapeutic target and clinical response biomarker for CRC.

Citing Articles

The RNA binding protein IGF2BP2/IMP2 alters the cargo of cancer cell-derived extracellular vesicles supporting tumor-associated macrophages.

Mashayekhi V, Schomisch A, Rasheed S, Aparicio-Puerta E, Risch T, Yildiz D Cell Commun Signal. 2024; 22(1):344.

PMID: 38937789 PMC: 11212187. DOI: 10.1186/s12964-024-01701-y.

Exploring the Key Signaling Pathways and ncRNAs in Colorectal Cancer.

Lee Y, Kim W, Park E, Lee D, Kim J, Shin H Int J Mol Sci. 2024; 25(8).

PMID: 38674135 PMC: 11050203. DOI: 10.3390/ijms25084548.

Role of Mir-452-5p Overexpression in Epithelial-Mesenchymal Transition (EMT) in Early-stage Colorectal Cancer.

Koyama Y, Fujihara S, Chiyo T, Matsui T, Hamaya S, Fujita K In Vivo. 2023; 37(5):1980-1990.

PMID: 37652512 PMC: 10500504. DOI: 10.21873/invivo.13295.

MicroRNA 452 regulates SHC1 expression in human colorectal cancer and colitis.

Mo J, Lamichhane S, Yun K, Chae S Genes Genomics. 2023; 45(10):1295-1304.

PMID: 37523129 DOI: 10.1007/s13258-023-01432-3.

miR-452-5p suppressed the metastasis of Non-small cell lung cancer through regulating Moesin.

Zhuang J, Fan J, Zhu L, Zhao L, Huang Y, Pan X J Cancer. 2023; 14(11):2015-2022.

PMID: 37497401 PMC: 10367917. DOI: 10.7150/jca.83221.

References

Wu C, Ng S, Dong Y, Tian L, Ng S, Leung W . Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res. 2014; 20(11):2994-3002. DOI: 10.1158/1078-0432.CCR-13-1750. View

Zhang D, Zhou Q, Huang D, He L, Zhang H, Hu B . ROS/JNK/c-Jun axis is involved in oridonin-induced caspase-dependent apoptosis in human colorectal cancer cells. Biochem Biophys Res Commun. 2019; 513(3):594-601. DOI: 10.1016/j.bbrc.2019.04.011. View

Maroney A, Finn J, Connors T, Durkin J, Angeles T, Gessner G . Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem. 2001; 276(27):25302-8. DOI: 10.1074/jbc.M011601200. View

Tryggestad J, Vishwanath A, Jiang S, Mallappa A, Teague A, Takahashi Y . Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. Clin Sci (Lond). 2016; 130(21):1955-67. PMC: 5516927. DOI: 10.1042/CS20160305. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

De Vriendt V, De Roock W, Di Narzo A, Tian S, Biesmans B, Jacobs B . DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. Biomarkers. 2013; 18(6):516-24. DOI: 10.3109/1354750X.2013.819038. View

Fang J, Richardson B . The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005; 6(5):322-7. DOI: 10.1016/S1470-2045(05)70168-6. View

Zheng Q, Sheng Q, Jiang C, Shu J, Chen J, Nie Z . MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B. Mol Cell Biochem. 2014; 389(1-2):187-95. DOI: 10.1007/s11010-013-1940-z. View

Zhai W, Li S, Zhang J, Chen Y, Ma J, Kong W . Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals. Mol Cancer. 2018; 17(1):157. PMC: 6231268. DOI: 10.1186/s12943-018-0906-x. View

10.

Song C, Chen H, Chen L, Ru G, Guo J, Ding Q . The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies. J Cell Biochem. 2017; 119(3):2763-2786. PMC: 5814937. DOI: 10.1002/jcb.26445. View

11.

Kim M, Jang K, Miller P, Picon-Ruiz M, Yeasky T, El-Ashry D . VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug. Oncogene. 2017; 36(36):5199-5211. PMC: 5596211. DOI: 10.1038/onc.2017.4. View

12.

Goto Y, Kojima S, Kurozumi A, Kato M, Okato A, Matsushita R . Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer. Br J Cancer. 2016; 114(10):1135-44. PMC: 4865980. DOI: 10.1038/bjc.2016.95. View

13.

Hou P, Li Y, Lin S, Lin S, Lee J, Lin B . Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness. Cancer Res. 2017; 77(16):4305-4316. DOI: 10.1158/0008-5472.CAN-16-2990. View

14.

Caunt C, Keyse S . Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 2012; 280(2):489-504. PMC: 3594966. DOI: 10.1111/j.1742-4658.2012.08716.x. View

15.

Liao W, Ye Y, Zhang N, Li T, Wang S, Cui Y . MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol. 2013; 232(4):415-27. DOI: 10.1002/path.4309. View

16.

Zhang F, Li K, Pan M, Li W, Wu J, Li M . miR-589 promotes gastric cancer aggressiveness by a LIFR-PI3K/AKT-c-Jun regulatory feedback loop. J Exp Clin Cancer Res. 2018; 37(1):152. PMC: 6048856. DOI: 10.1186/s13046-018-0821-4. View

17.

Liu Y, Chen X, Cheng R, Yang F, Yu M, Wang C . The Jun/miR-22/HuR regulatory axis contributes to tumourigenesis in colorectal cancer. Mol Cancer. 2018; 17(1):11. PMC: 5775639. DOI: 10.1186/s12943-017-0751-3. View

18.

Kugler N, Klein K, Zanger U . MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation. Biochem Pharmacol. 2019; 171:113725. DOI: 10.1016/j.bcp.2019.113725. View

19.

Hu Q, Chen W, Zhong S, Zhang J, Ma T, Ji H . MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells. Tumour Biol. 2014; 35(7):6327-34. DOI: 10.1007/s13277-014-1834-z. View

20.

Chen X, Lu P, Wang D, Yang S, Wu Y, Shen H . The role of miRNAs in drug resistance and prognosis of breast cancer formalin-fixed paraffin-embedded tissues. Gene. 2016; 595(2):221-226. DOI: 10.1016/j.gene.2016.10.015. View